Previous close | 48.99 |
Open | 49.00 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1400 |
Day's range | 48.55 - 49.04 |
52-week range | 47.58 - 69.10 |
Volume | |
Avg. volume | 15,456,937 |
Market cap | 99.027B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 12.66 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.40 (4.91%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | N/A |
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.